| Genetic Signatures Limited (GSS) ORDINARY FULLY PAID |
Health Care |
$19 |
Genetic Signatures Organisational Restructure
|
30 Mar 2026 9:08AM |
$0.088 |
$0.083 |
fallen by
5.68%
|
|
GSS - Price-sensitive ASX Announcement
Full Release
Key Points
- Organisational restructure to reduce costs and improve efficiency.
- Estimated cost savings of $5 million from FY2027.
- Redundancies and transition to outsourced product development.
- Focus on sales growth and customer support.
- Expansion of diagnostic product offering.
- Restructure aims to enhance operational discipline and support growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ironbark Balanced Income Limited (IBC) ORDINARY FULLY PAID |
Financials |
$44 |
Update - Notification of buy-back - IBC
|
30 Mar 2026 9:05AM |
$0.430 |
$0.435 |
risen by
1.16%
|
|
| IVE Group Limited (IGL) ORDINARY FULLY PAID |
Communication Services |
$401 |
Update - Notification of buy-back - IGL
|
30 Mar 2026 9:04AM |
$2.530 |
$2.610 |
risen by
3.16%
|
|
| Dicker Data Limited (DDR) ORDINARY FULLY PAID |
Information Technology |
$1,624 |
Annual General Meeting
|
30 Mar 2026 9:01AM |
$8.540 |
$8.970 |
risen by
5.04%
|
|
| Valiant Gold Limited (VAL) ORDINARY FULLY PAID |
Materials |
$90 |
IPO Successfully Completed
|
30 Mar 2026 8:59AM |
$0.300 |
$0.300 |
fallen by
0%
|
|
| Australian Foundation Investment Company Limited (AFI) ORDINARY FULLY PAID |
Financials |
$8,195 |
Update - Notification of buy-back - AFI
|
30 Mar 2026 8:59AM |
$6.640 |
$6.560 |
fallen by
1.20%
|
|
| Cynata Therapeutics Limited (CYP) ORDINARY FULLY PAID |
Health Care |
$77 |
Last Visit in GvHD Trial Completed
|
30 Mar 2026 8:58AM |
$0.300 |
$0.323 |
risen by
7.50%
|
|
CYP - Price-sensitive ASX Announcement
Full Release
Key Points
- Completion of 100-day primary evaluation period for Phase 2 aGvHD trial
- 65 participants in randomized, double-blind, placebo-controlled trial
- Primary endpoint is Overall Response Rate at Day 28
- 87% Overall Response and 53% Complete Response in Phase 1 trial
- CYP-001 designed to improve response rates and survival outcomes
- Orphan Drug Designation by US FDA for CYP-001
- No serious adverse events reported for CYP-001 treatment
- Cynata Therapeutics focuses on stem cell and regenerative medicine
- Cymerus™ platform overcomes conventional MSC production challenges
- Upcoming results expected in June 2026
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| SPDR S&P/ASX 200 Fund (STW) |
Financials |
$6,298 |
Update - Dividend/Distribution - STW
|
30 Mar 2026 8:58AM |
$77.100 |
$77.870 |
risen by
1%
|
|
| Challenger Limited (CGF) ORDINARY FULLY PAID |
Financials |
$5,865 |
Update - Notification of buy-back - CGF
|
30 Mar 2026 8:58AM |
$8.200 |
$8.505 |
risen by
3.72%
|
|
| AMCIL Limited (AMH) ORDINARY FULLY PAID |
Financials |
$291 |
Update - Notification of buy-back - AMH
|
30 Mar 2026 8:58AM |
$0.920 |
$0.920 |
fallen by
0%
|
|
| EML Payments Limited (EML) ORDINARY FULLY PAID |
Financials |
$169 |
Global CEO Appointment and Australian Regulatory Update
|
30 Mar 2026 8:57AM |
$0.575 |
$0.435 |
fallen by
24.35%
|
|
EML - Price-sensitive ASX Announcement
Full Release
Key Points
- Adam Olding appointed as Global CEO of EML Payments Limited effective 30 March 2026.
- Olding has been leading EML’s Australia, UK, and Europe businesses and brings experience in payments, governance, and business transformation.
- The appointment supports EML’s EML2.0 transformation program and strategic growth priorities.
- EML Payment Solutions Limited is progressing an application with APRA for an ADI licence for its prepaid card programs.
- APRA and RBA require EML to obtain a guarantee from an ADI in respect of stored value liabilities by 30 April 2026.
- EML holds customer funds on trust, segregated in accounts with a tier one Australian bank.
- The Australian Government is proposing reforms to lessen the regulatory burden on purchased payment facility providers like EML.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$172 |
Update - Notification of buy-back - BBT
|
30 Mar 2026 8:57AM |
$0.205 |
$0.165 |
fallen by
19.51%
|
|
| Viva Leisure Limited (VVA) ORDINARY FULLY PAID |
Consumer Discretionary |
$150 |
Update - Notification of buy-back - VVA
|
30 Mar 2026 8:57AM |
$1.560 |
$1.520 |
fallen by
2.56%
|
|
| SPDR S&P/ASX 200 Listed Property Fund (SLF) |
Financials |
$490 |
Update - Dividend/Distribution - SLF
|
30 Mar 2026 8:57AM |
$11.430 |
$12.430 |
risen by
8.75%
|
|
| Regal Investment Fund (RF1) ORDINARY UNITS FULLY PAID |
Financials |
$726 |
Update - Notification of buy-back - RF1
|
30 Mar 2026 8:57AM |
$3.400 |
$3.470 |
risen by
2.06%
|
|
| Flight Centre Travel Group Limited (FLT) ORDINARY FULLY PAID |
Consumer Discretionary |
$2,104 |
Update - Notification of buy-back - FLT
|
30 Mar 2026 8:56AM |
$10.970 |
$10.205 |
fallen by
6.97%
|
|
| Algorae Pharmaceuticals Limited (1AI) ORDINARY FULLY PAID |
Health Care |
$26 |
Peter Mac Partners with Algorae on AI Validation
|
30 Mar 2026 8:56AM |
$0.017 |
$0.013 |
fallen by
23.53%
|
|
1AI - Price-sensitive ASX Announcement
Full Release
Key Points
- Algorae Pharmaceuticals partners with Peter MacCallum Cancer Centre for AI-driven drug synergy screening.
- Twenty-four high-priority drug combination candidates will be screened across four cancer cell lines.
- The project is expected to generate preclinical data within six months.
- AOS2 predicted set comprises CBD in combination with over 3,000 drugs evaluated across 170 cell lines.
- AOS2 outperformed models from Google DeepMind with stronger calibration.
- The collaboration aims to confirm efficacy of drug combinations.
- The study includes optimizing cell growth conditions and quantifying treatment effects.
- Successful validation could support further development and partnership opportunities.
- Peter MacCallum Cancer Centre is a leading cancer research institution in Australia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Barton Gold Holdings Limited (BGD) ORDINARY FULLY PAID |
Materials |
$212 |
$520,000 Cash R&D Tax Refund Received
|
30 Mar 2026 8:55AM |
$0.840 |
$0.885 |
risen by
5.36%
|
|
BGD - Price-sensitive ASX Announcement
Full Release
Key Points
- Barton Gold Holdings Limited received a $520,000 cash R&D tax refund for the year ended 30 June 2025.
- The refund was received under the Australian Federal Government's R&D Tax Incentive Program.
- The company's unrestricted cash balance is approximately $13.5 million, excluding funds posted as security.
- Barton Gold has been conducting R&D programs focused on developing new exploration methodologies and geological models in South Australia.
- Significant exploration outcomes have been achieved at the Tarcoola and Tunkillia projects.
- The R&D programs are expected to continue into the 2026 and 2027 financial years.
- The tax incentive has facilitated significant advancements in exploration activities and efficiencies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Fitzroy River Corporation Ltd (FZR) ORDINARY FULLY PAID |
Energy |
$18 |
Update on Snowy River Gold Project
|
30 Mar 2026 8:54AM |
$0.175 |
$0.170 |
fallen by
2.86%
|
|
FZR - Price-sensitive ASX Announcement
Full Release
Key Points
- Fitzroy River Corporation Ltd received a payment on behalf of Tasman Mining Limited.
- The payment of A$12,265,134 was for Tasman exercising an option to acquire Fitzroy's royalty over the Snowy River Gold Project.
- The Snowy River Royalty is a variable 1-3% royalty with a buy-out option.
- The buy-out price is adjusted quarterly for CPI from a baseline value of A$11.6m as of March 2024.
- A decision to mine is determined when Tasman has sufficient funds to complete the project and pay the buy-out price.
- If the buy-out option is not exercised, Fitzroy is entitled to royalty payments if the project reaches commercial production.
- Fitzroy is holding the received funds in escrow until further confirmation from Tasman.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hearts and Minds Investments Limited (HM1) ORDINARY FULLY PAID |
Financials |
$662 |
Weekly NTA Estimate
|
30 Mar 2026 8:54AM |
$2.760 |
$2.890 |
risen by
4.71%
|
|
| SPDR S&P/ASX 50 Fund (SFY) |
Financials |
$710 |
Update - Dividend/Distribution - SFY
|
30 Mar 2026 8:54AM |
$75.380 |
$75.810 |
risen by
0.57%
|
|
| West Cobar Metals Limited (WC1) ORDINARY FULLY PAID |
Materials |
$7 |
Salazar Heap Leach Potential Supported by Testwork
|
30 Mar 2026 8:53AM |
$0.018 |
$0.021 |
risen by
16.67%
|
|
WC1 - Price-sensitive ASX Announcement
Full Release
Key Points
- WC1 has achieved significant progress with the Salazar Project.
- Salazar Heap Leach Potential is supported by recent test work.
- Metallurgical testing shows promising results for copper extraction.
- Sulphuric acid leaching resulted in up to 87% copper recovery.
- West Cobar Metals Limited continues to advance the Salazar Project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Rimfire Pacific Mining Limited (RIM) ORDINARY FULLY PAID |
Materials |
$31 |
Proposed issue of securities - RIM
|
30 Mar 2026 8:53AM |
$0.012 |
$0.011 |
fallen by
8.33%
|
|
| 88 Energy Limited (88E) ORDINARY FULLY PAID |
Energy |
$32 |
Augusta-1 Exploration Well Planning and Permitting Underway
|
30 Mar 2026 8:53AM |
$0.033 |
$0.024 |
fallen by
27.27%
|
|
| JB Hi-Fi Limited (JBH) ORDINARY FULLY PAID |
Consumer Discretionary |
$8,555 |
Notification regarding unquoted securities - JBH
|
30 Mar 2026 8:52AM |
$75.570 |
$78.250 |
risen by
3.55%
|
|
Call 1300 880 160
Start a chat
Schedule a call
